OncoSec Medical Inc., a Pennington-based cancer immunotherapy developer, announced on Monday that Kellie Malloy Foerter has been appointed to chief operating officer, effective immediately.
Foerter, who joined OncoSec in 2018 as the company’s chief clinical development officer, will be responsible for the company’s financing, engineering and HR functions while continuing her leadership in clinical operations.
“Kellie is the perfect operational leader for OncoSec at this pivotal time in our growth,” Daniel J. O’Connor, CEO and president, OncoSec, said. “She is a results-driven leader with a deep understanding of every aspect of our business and a has proven track record of accomplishment and success. As we move into the second half of 2020, Kellie’s leadership will be instrumental in completing enrollment in the KEYNOTE-695 study and reporting an interim data update this fall, as well as driving operational success and increasing shareholder value. We congratulate Kellie on her new role and look forward to her expanded operational guidance and leadership.”
Prior to OncoSec, Foerter was a senior executive at Syneos Health, having spent more than 21 years at the company which was formerly called inVentiv Health and PharmaNet. Prior to her two decades at Syneos, she began her career at Covance.